1. 1) Shah V. P., Midha K. K., Dighe S. V., Pharm. Res., 9, 588-592 (1992).
2. 2) U.S. Food and Drug Administration. “Guidance for Industry: Bioanalytical Method Validation.”: 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf〉, cited 5 September, 2014.
3. 3) European Medicines Agency. “Guideline on Bioanalytical Method Validation.”: 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf〉, cited 5 September, 2014.
4. 4) Ministry of Health, Labour and Welfare. “Guideline on Bioanalytical Method Validation in Pharmaceutical Development.”: 〈http://www.nihs.go.jp/drug/BMV/250711_BMV-GL.pdf〉, National Institute of Health Sciences Web, cited 5 September, 2014.
5. 5) Briggs R. J., Nicholson R., Vazvaei F., Busch J., Mabuchi M., Mahesh K. S., Brudny-Kloeppel M., Weng N., Galvinas P. A. R., Duchene P., Hu P., Abbott R. W., AAPS J., 16, 1143-1148 (2014).